ClinicalTrials.gg
RecruitingNCT04867187STIRMUpdated May 8, 2026

rTMS Efficacy Coupled With Mirror Therapy

An interventional study of Repetitive transcranial magnetic stimulation (rTMS) and Mirror therapy using virtual reality in Neuropathic Pain, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 2 sites in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 132 studies in Neuralgia with a site in France — 39 open to participants now, 40 under way, 4 of them phase 3. Neuralgia · France.

Planned enrollment
50th of 102
64 · median 62
Started
2022
with 4 others
No phase
46 of 132
23 open now
Primary completion
2026-12
later than 9 of 39 live
Registered
83rd of 132
by date
Lead sponsor
9 of 132
Centre Hospitalier Universitaire de Saint Etienne

Among the 132 studies in Neuralgia with a site in France, this one is the 50th largest by planned enrollment of the 102 interventional ones that give a count, is one of 5 that started in 2022, is one of 46 with no phase, reaches primary completion later than 9 of the 39 other live ones, and was the 83rd registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

39 of the 132 studies in Neuralgia with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Neuralgia with a site in France, or all of them as a file.
02

Study summary

Neuropathic pain is particularly difficult to treat with classic first-line drugs. Neuromodulation techniques using repetitive transcranial magnetic stimulation (rTMS) are useful alternative, but there is a need to improve their analgesic effect.Virtual reality mirror therapy has shown the capacity to alleviate pain and may be easily coupled with rTMS.The present project will investigate in individuals with neuropathic pain the effects of the rTMS coupled with virtual reality mirror therapy.

Read the detailed description

This project introduces a new research question that incorporates virtual reality mirror therapy into an established treatment protocol of repetitive transcranial magnetic stimulation (rTMS) for neuropathic pain relief. Neuropathic pain is particularly difficult to treat with classic first-line drugs. Neuromodulation techniques using repetitive transcranial magnetic stimulation (rTMS) are useful alternative, but there is a need to improve their analgesic effect.

Virtual reality mirror therapy has shown the capacity to alleviate pain and may be easily coupled with rTMS. The efficacy of using both techniques in neuropathic pain treatment is unknown. The present project will investigate in individuals with neuropathic pain the effects of the rTMS coupled with virtual reality mirror therapy on: 1) daily pain intensity (i.e. analgesic efficacy); 2) other components of pain and the quality of life; 3) brain activity.

It will be the first to provide insight into the efficacy of using together both non-invasive technics of cortical neuromodulation to alleviate pain.

03

Conditions studied

  • Neuropathic Pain

Browse trials for

Keywords

  • transcranial magnetic stimulation
  • virtual reality
  • mirror therapy
  • brain networks
  • predictive model
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical symptoms typical of neuropathic pain
  • to drug therapies
  • Lasting for at least 6 months, with a moderate to severe pain intensity (≥4/10 on Visual Analog Scale, VAS) and a stable pain treatment since 1month at least
  • Having right to health benefits

Exclusion criteria

Exclusion Criteria:

  • Ferromagnetic components and implanted microprocessors (i.e. cochlear implants)
  • Drug-resistant or active epilepsy, pacemaker, pregnancy, ongoing depression or personality troubles, and ongoing opioid treatment.
  • Any other to MRI scanner (e.g., claustrophobia, etc.).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    rTMS active and active mirror-based therapy using virtual reality

    The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and active mirror-based therapy using virtual reality.

    Other: Repetitive transcranial magnetic stimulation (rTMS) · Other: Mirror therapy using virtual reality

  • Sham comparator
    rTMS active and sham mirror-based therapy using virtual reality

    The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and sham mirror-based therapy using virtual reality.

    Other: Repetitive transcranial magnetic stimulation (rTMS) · Other: Mirror therapy using sham mirror

Interventions

  • OtherRepetitive transcranial magnetic stimulation (rTMS)

    20 minutes of high frequency (20Hz) rTMS.

  • OtherMirror therapy using virtual reality

    active mirror-based therapy

  • OtherMirror therapy using sham mirror

    20 minutes of sham mirror-based therapy

06

What researchers measure

Primary outcomes

  1. Pain intensity measurement

    Averages of the daily visual analogue scale scores (min no pain max pain imaginable) measured during the first week (Week 1) and that measured during the week following the last session (week 9)

    Time frame: Week 9

Secondary outcomes

  1. Quality of life after treatment

    EQ5D scale (min = 0 worst imaginable health condition and max = 100 best health condition imaginable) and Analgesic consumption of Appeal

    Time frame: week 12

  2. Spontaneous brain activity

    Functional MRI at rest

    Time frame: week 12

  3. neuropathic dimension

    overall score of the neuropathic pain symptoms inventory (NPSI) (min = 0 no neuropathic pain and max = 100 intensive neuropathic pain)

    Time frame: Week 3, 5, 7, 9,12

  4. Adverse events

    Nature and number of adverse events

    Time frame: Week 3, 5, 7, 9,12

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.

Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 50 months is above that.

Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2021
First posted
Apr 30, 2021
StartActual
Oct 27, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04867187
Responsible party
Sponsor
First posted
Apr 30, 2021
Start date
Oct 27, 2022
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 8, 2026

Study contacts

Roland Peyron, MDPHD
Contact
roland.peyron@univ-st-etienne.fr
(0)477825684 ext. +33
Beatrice DEYGAS, CRA
Contact
beatrice.deygas@chu-st-etienne.fr
Roland Peyron, MDPHD
principal investigator · CENTRE HOSPITALIER DE SAINT-ETIENNE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion